(Q48423410)

English

Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.

scientific article published on 18 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

blood–brain barrier

1 reference

based on heuristic

inferred from title

author name string

Yasuhisa Nagasaka

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Kazuo Oda

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Takafumi Iwatsubo

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Akio Kawamura

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Takashi Usui

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

publication date

18 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Biopharmaceutics and Drug Disposition

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

33

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

6

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

304-315

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Membrane transporters in drug development

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Mrp4 confers resistance to topotecan and protects the brain from chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic a

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Risperidone and paliperidone inhibit p-glycoprotein activity in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Antipsychotic drugs inhibit the function of breast cancer resistance protein

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Aripiprazole brain concentration is altered in P-glycoprotein deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Drug interactions at the blood-brain barrier: fact or fantasy?

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Pharmacokinetics of quinidine related to plasma protein binding in man

1 reference

https://api.crossref.org/works/10.1002%2FBDD.1801

21 January 2018

Identifiers

10.1002/BDD.1801

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22847220

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48423410&oldid=1199318057"